Hazem F M Abdelaal

Person icon

Postdoctoral Scientist

Coler Lab at Centre for Global Infectious Disease Research, Seattle Children’s Research Institute

Email: Hazem.abdelaal@seattlechildrens.org  

 

 

 

 

VALIDATE Role: Network Associate

 

Research Keywords

Preclinical model of TB, molecular pathogenesis functional genomics

Biography

I received my Ph.D. in the Comparative Biomedical Science (CBMS) program, University of Wisconsin-Madison. Understanding the virulence mechanisms of Mycobacterium tuberculosis infection. My endless passion was always to work in mycobacterial research. In my current role as Postdoctoral scientist in the Coler Lab at Seattle Children’s Research Institute (SCRI) I work on advancing the diagnostic approaches for early detection of Mycobacterium tuberculosis and other nontuberculous mycobacteria (NTM). We develop novel and translational preclinical models of mycobacterial disease, examine pathology as a critical efficacy readout, assess innate and adaptive immune responses to vaccination, and strive to elucidate immune correlates of protection.

Key publications

  • Abdelaal HFM, Thacker TC, Wadie B, Palmer MV, & Talaat AM. (2022). Transcriptional Profiling of Early and Late Phases of Bovine Tuberculosis. Infection and Immunity, 90(2), e0031321. doi.org/10.1128/IAI.00313-21
  • Abdelaal HFM, Spalink D, Amer A, Steinberg H, Hashish EA, Nasr EA, Talaat AM. Genomic Polymorphism Associated with the Emergence of Virulent Isolates of Mycobacterium bovis in the Nile Delta. Sci Rep 9, 11657 (2019). doi:10.1038/s41598-019-48106-3.
  • Sharma J, Mudalagiriyappa S, Abdelaal HFM, Kelly TC, Choi W, Vieson, MD, Talaat AM, & Nanjappa SG. (2021). Uncovering the role of CBLB for innate immune responses regulating systemic dissemination during a Non-Tuberculous Mycobacterial infection. The Journal of Immunology, 206. no. 1 Supplement 110.14
  • Ali HR, Ali MRK, Wu Y, Selim SA, Abdelaal HFM, Nasr EA, El-Sayed MA. Gold Nanorods as Drug Delivery Vehicles for Rifampicin Greatly Improve the Efficacy of Combating Mycobacterium tuberculosis with Good Biocompatibility with the Host Cells. Bioconjugate Chemistry 2016, 27 (10), 2486-2492. doi:10.1021/acs.bioconjchem.6b00430

Weblinks of interest